RecruitingPhase 1NCT05683418
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Totus Medicines
- Principal Investigator
- Zelanna Goldberg, MDTotus Medicines
- Intervention
- TOS-358(drug)
- Enrollment
- 241 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (18)
- University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
- NEXT Oncology - Hospital Quironsalud Barcelona - PPDS, Barcelona, Spain
- START Barcelona HM Nou Delfos, Barcelona, Spain
- Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona, Spain
- Hospital Clinico San Carlos, Madrid, Spain
- START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS, Madrid, Spain
- START MADRID Hospital Universitario HM Sanchinarro - CIOCC, Madrid, Spain
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05683418 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →